14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BCAX vs UPB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Bicara Therapeutics Inc. (BCAX) captures the overall head-to-head institutional edge over Upstream Bio, Inc. (UPB) on higher Unified Composite conviction (52.1/100 HOLD vs. 43.6/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Options & Positioning), while UPB wins 3–2 across the 6-pillar growth and valuation breakdown. BCAX trades at $9.75 (N/M Forward P/E, 0.0% operating margin) versus UPB at $2.15 (N/M Forward P/E, -6116.0% operating margin).
Growth vs. Quality Trade-Off: BCAX earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. UPB 43.6/100 HOLD) and 1.42β · 184% Vol risk profile, whereas UPB leads top-line expansion (-42.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile UPB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs UPB. Trailing 12-month operating profitability (BCAX 0.0% vs UPB -6116.0%) and valuation multiples (BCAX N/M vs UPB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $156.8M market capitalization and -6116.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BCAX vs UPB Key Questions & Quantitative Answers
As of Nov 16, 2026, Bicara Therapeutics Inc. (BCAX) captures the overall head-to-head institutional edge over Upstream Bio, Inc. (UPB) on higher Unified Composite conviction (52.1/100 HOLD vs. 43.6/100 HOLD) after splitting the core matrix 5–2 (led by Growth & Scale, Options & Positioning), while UPB wins 3–2 across the 6-pillar growth and valuation breakdown. BCAX trades at $9.75 (N/M Forward P/E, 0.0% operating margin) versus UPB at $2.15 (N/M Forward P/E, -6116.0% operating margin). Growth vs. Quality Trade-Off: BCAX earns the overall head-to-head edge with a stronger Unified Composite Score (52.1/100 HOLD vs. UPB 43.6/100 HOLD) and 1.42β · 184% Vol risk profile, whereas UPB leads top-line expansion (-42.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile UPB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BCAX leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with UPB at -42.2% YoY revenue growth and +0.0% YoY earnings growth on $2.9M TTM revenue (100.0% gross margin, -6116.0% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus $2.9M for UPB. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UPB.
UPB screens cheaper on headline valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas UPB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 38.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus UPB (-53.5% ROE) capital efficiency.
In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 184% Vol realized risk). By comparison, UPB carries 86.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 4.72x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.